Gilead, LEO Pharma
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal wit | Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now,
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...
After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...
Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback